ライフサイエンスコーパス: axillary

1 -80 years) underwent high-spatial-resolution axillary 3.0-T T2-weighted imaging without fat suppressi

2 Percutaneous axillary access for use with microaxial support pumps ap

3 The Axillary Access Registry to Monitor Safety (ARMS) was a

4 tive LR, 3.1 [95% CI, 1.6-5.9]), inguinal or axillary adenopathy (specificity range, 0.82-0.91; posit

5 T1 or T2 invasive breast cancer, no palpable axillary adenopathy, and 1 or 2 sentinel lymph nodes con

6 invasive primary breast cancer, no palpable axillary adenopathy, and 1 or 2 sentinel lymph nodes con

7 presence of posterior cervical, inguinal or axillary adenopathy, palatine petechiae, splenomegaly, o

8 There was no palpable axillary adenopathy.

9 severe truncal hirsutism and higher rates of axillary AN.

10 Patients with axillary and breast pCR after PST had superior long-term

11 ternal mammary nodes and the supraclavicular-axillary apical nodes in addition to the chest wall or r

12 Axillary artery access is an option for these patients,

13 n five locations (forehead, nasolabial area, axillary, backhand, and palm), bilaterally, on two diffe

14 We collected and tested axillary, blood, conjunctival, forehead, mouth, rectal,

15 ngth distribution and consensus sequences in axillary, brachial, inguinal, and mesenteric LNs were vi

16 Axillary branch suppression is a favorable trait bred in

17 Here, we show that tb1 mediates axillary branch suppression through direct activation of

18 nated from ectopic overexpression of tru1 in axillary branches, a critical step in mediating the effe

19 , with longer stems, smaller seeds and fewer axillary branches.

20 apical dominance, displaying greatly reduced axillary branching compared to their wild ancestors.

21 o) and phosphate availability, such that the axillary bud at node 7 varied from deeply dormant to rap

22 at axil and leaf boundary regions to control axillary bud differentiation as well as the development

23 ristem arrest by repressing genes related to axillary bud dormancy in the SAM and negative regulators

24 scription factor that acts as a repressor of axillary bud growth.

25 he miR156 targets, directly regulated aerial axillary bud initiation.

26 reby the impact of any SL signal reaching an axillary bud is modulated by the responsiveness of these

27 accelerated spikelet initiation and reduced axillary bud number in a photoperiod-independent manner

28 Axillary bud outgrowth in general is negatively regulate

29 ation of decapitation- and cytokinin-induced axillary bud outgrowth is independent of auxin canalizat

30 Inhibitory effects of PCIB and NPA on axillary bud outgrowth only became apparent from 48 h af

31 mental signals involved in the regulation of axillary bud outgrowth.

32 seq, hormone and sugar measurements on 1 mm axillary bud tissue, we identify the genetic pathways pu

33 ght and nutrition, are integrated within the axillary bud to promote or suppress the growth of the bu

34 ision during branch development: whether the axillary bud, or branch primordium, grows out to give a

35 whereby the shoot tip inhibits the growth of axillary buds along the stem.

36 etween specific changes in auxin efflux from axillary buds and bud outgrowth after shoot tip removal

37 otein (RanBP) in Arabidopsis results in more axillary buds and reduced apical dominance compared to W

38 the main stem and inhibits the growth of the axillary buds below it, contributing to apical dominance

39 fruit removal resembled changes observed in axillary buds following release from apical dominance.

40 ipt is regulated by light quality, such that axillary buds growing in added far-red light have greatl

41 The outgrowth of axillary buds into branches is regulated systemically vi

42 ppressing auxin canalization and export from axillary buds into the main stem.

43 In this theory, auxin flow out of axillary buds is a prerequisite for bud outgrowth, and b

44 rs are vegetative branches that develop from axillary buds located in the leaf axils at the base of m

45 ism underlying NtBRC2A-mediated outgrowth of axillary buds needs to be further addressed.

46 PCIB), effectively blocked auxin efflux from axillary buds of intact and decapitated plants without a

47 Colchicine treatment of axillary buds resulted in a set of autotetraploid S. vim

48 le, and biosynthesis and transport genes, in axillary buds within 3 h after application.

49 The expression of TRU1 and TB1 overlap in axillary buds, and TB1 binds to two locations in the tru

50 Grasses possess basal and aerial axillary buds.

51 abidopsis is determined by the activation of axillary buds.

52 1 promotes branching through local action in axillary buds.

53 nins and strigolactones, which can move into axillary buds.

54 llary staging procedures to ALND to identify axillary burden after NST in patients with pathologicall

55 served across all operative subphases on the axillary clearance assessment tool (P < 0.001).

56 Despite the potential for residual axillary disease after SLND, SLND without ALND offers ex

57 For patients with residual axillary disease, 10-year OS rates were 66% (95% CI, 56%

58 demonstrated reduced size of the breast and axillary disease, and no significant residual PET avidit

59 for patients with axillary pCR and residual axillary disease, respectively.

60 01) for those with axillary pCR and residual axillary disease, respectively.

61 radioactive iodine seed (MARI), and targeted axillary dissection (a combination of SLNB and a MARI-li

62 2,M0 breast cancer underwent SLN surgery and axillary dissection (ALND) after neoadjuvant chemotherap

63 To determine rates of axillary dissection (ALND) and nodal recurrence in patie

64 target lymph node (TLN) biopsy and targeted axillary dissection (TAD) in routine clinical practice.

65 he status of the nodal basin and if targeted axillary dissection (TAD), which includes sentinel lymph

66 When clinicians and patients elect to omit axillary dissection after a positive sentinel node biops

67 Targeted axillary dissection or selective removal of lymph nodes

68 d selectively removed to accomplish targeted axillary dissection, which is technically possible after

69 is noninferior to that of women treated with axillary dissection.

70 nt (30 of 30 [100%] for readers 1 and 2) and axillary (eight of eight [100%] for reader 1, seven of e

71 volume was the most significant predictor of axillary evaluation among women undergoing BCS (mid vs l

72 ective evaluation of the clinical benefit of axillary evaluation in women with DCIS is needed.

73 Rates of axillary evaluation increased over time with mastectomy

74 Despite uncertainty regarding the efficacy, axillary evaluation is often performed in women with DCI

75 Receipt or nonreceipt of surgical axillary evaluation, categorized as sentinel lymph node

76 g BCS and 63.0% undergoing mastectomy had an axillary evaluation.

77 was used to identify factors associated with axillary evaluation.

78 No SNB-only patient developed axillary failure.

79 and redundant roles in the specification of axillary floral meristems and lemma identity.

80 rets, each including a bract (lemma) with an axillary flower.

81 ENSITIVE 2 (KAI2) and the F-box protein MORE AXILLARY GROWTH 2 (MAX2) mediates a range of development

82 alpha/beta-fold hydrolase and the MAX2 (MORE AXILLARY GROWTH 2) F-box leucine-rich protein, which tog

83 (Skp, Cullin, F-box) complex component MORE AXILLARY GROWTH2 (MAX2) [3-5].

84 Both pathways require the F-box protein MORE AXILLARY GROWTH2 (MAX2), and other core signaling compon

85 sis thaliana requires the F-box protein MORE AXILLARY GROWTH2 (MAX2).

86 pubertal milestones-including Tanner stages, axillary hair growth, and age at menarche or voice break

87 bout 1.5-3 months earlier age at pubic hair, axillary hair, and acne development comparing unexposed

88 equired for the development of multicellular axillary hairs on the gametophyte of the moss Physcomitr

89 We confirm that even without preoperative axillary imaging or routine use of nodal RT, ALND can be

90 Axillary imaging was not routine.

91 esses and pus-discharging tunnels develop in axillary, inguinal, gluteal and perianal body sites.

92 of human NF1: [1] cafe-au-lait macules, [2] axillary/inguinal freckling, [3] shortened stature, [4]

93 y expressed in the leaf trace vasculature of axillary internodes, while in teosinte, this expression

94 able beyond 10 years, even for those with no axillary involvement (2.0%, 2.1%, and 1.1% for years 10

95 lvement, or an externally located tumor with axillary involvement to undergo either whole-breast or t

96 ological tumour size >20 mm, with or without axillary involvement), at 66 centres in the UK.

97 ially located primary tumor, irrespective of axillary involvement, or an externally located tumor wit

98 size, between SUVmax-T values and metastatic axillary LN size, between SUVmax-T and SUVmax-LN values,

99 lary LNs, between tumour size and metastatic axillary LN size, between SUVmax-T values and metastatic

100 PET/CT parameters including tumour size, axillary LN size, SUVmax of ipsilateral axillary LNs (SU

101 ad the lowest LN activity (mean [SD] maximum axillary LN standardized uptake value, 1.53 [0.56]), the

102 intermediate levels of LN (mean [SD] maximum axillary LN standardized uptake value, 2.12 [0.87] and 2

103 had the highest activity (mean [SD] maximum axillary LN standardized uptake value, 8.82 [3.08]).

104 ize, axillary LN size, SUVmax of ipsilateral axillary LNs (SUVmax-LN), SUVmax of primary tumour (SUVm

105 the size and SUVmax-LN values of metastatic axillary LNs, between tumour size and metastatic axillar

106 f the primary tumour and those of metastatic axillary LNs.

107 accurate exclusion of clinically significant axillary lymph node (ALN) disease.

108 group included 17 patients with ipsilateral axillary lymph node (LN) metastases.

109 went clip insertion into the most suspicious axillary lymph node (LN) were eligible.

110 P < .001), high body mass index ( P = .039), axillary lymph node dissection ( P = .008), and more sev

111 cer diagnosis ( P = .0404), having undergone axillary lymph node dissection ( P = .0464), and receipt

112 l lymph node biopsy (SLNB) alone, SLNB+RLNR, axillary lymph node dissection (ALND) alone, and ALND+RL

113 SLNB has replaced axillary lymph node dissection (ALND) as the staging mod

114 l lymph node dissection (SLND) alone without axillary lymph node dissection (ALND) is noninferior to

115 n both sentinel lymph node biopsy (SLNB) and axillary lymph node dissection (ALND) may be because of

116 inel lymph nodes (SLNs) randomized either to axillary lymph node dissection (ALND) or sentinel lymph

117 After NAC, SLN surgery and axillary lymph node dissection (ALND) were planned.

118 LE is a serious complication of axillary lymph node dissection (ALND) with an incidence

119 ve been proposed to replace the conventional axillary lymph node dissection (ALND) with its concomita

120 orized as sentinel lymph node biopsy (SLNB), axillary lymph node dissection (ALND), or none.

121 mph node (SLN) metastases should not receive axillary lymph node dissection (ALND).

122 performed with or without SLNB, TLNB, and/or axillary lymph node dissection (ALND).

123 the breast and regional nodes after BCS and axillary lymph node dissection (Group 1) were compared t

124 included body mass index >/= 25 (P = .0236), axillary lymph node dissection (P < .001), regional lymp

125 Axillary lymph node dissection (P < 0.0001), higher body

126 d the localized lymph node before completion axillary lymph node dissection and used radiography of t

127 lar to upfront SLNB and reduces the need for axillary lymph node dissection compared with SLNB prior

128 me progressively less extensive, with formal axillary lymph node dissection confined to a dwindling g

129 Indications for omission of completion axillary lymph node dissection in patients with two or f

130 These findings do not support routine use of axillary lymph node dissection in this patient populatio

131 the ability to achieve the results of total axillary lymph node dissection without the risks of surg

132 of node-positive patients and of completion axillary lymph node dissection) were analyzed to rule ou

133 eoadjuvant chemotherapy reduces the need for axillary lymph node dissection, and SLNB is an accurate

134 We have previously found that axillary lymph node dissection, both clinically and in a

135 y, followed by breast-conserving surgery and axillary lymph node dissection, which revealed residual

136 r to overall survival for those treated with axillary lymph node dissection.

137 s of any size continue to mandate completion axillary lymph node dissection.

138 is an accurate, less invasive alternative to axillary lymph node dissection.

139 of NAC, all patients had breast surgery with axillary lymph node dissection.

140 either sentinel lymph node biopsy (SLNB) or axillary lymph node dissection.

141 Although axillary lymph node evaluation is standard of care in th

142 had a breast pCR and 100% had no evidence of axillary lymph node metastases after NCT.

143 in the breast is correlated with absence of axillary lymph node metastases at final pathology (ypN0)

144 coefficient (ADC) value in the detection of axillary lymph node metastasis.

145 primary tumor subclones, or subclones in an axillary lymph node metastasis.

146 t to substitute it for SLNB for exclusion of axillary lymph node metastasis.

147 otal, 47 paired breast tumour and metastatic axillary lymph node samples were collected in this study

148 The MARI procedure [marking the axillary lymph node with radioactive iodine (I) seeds] i

149 s sentinel lymph node biopsy (SLNB), marking axillary lymph node with radioactive iodine seed (MARI),

150 on in both peripheral blood and the draining axillary lymph node, indicating significant BCG vaccine-

151 needle aspiration of a palpable, ipsilateral axillary lymph node.

152 e morphological characteristic of metastatic axillary lymph node.

153 Axillary lymph nodes (ALNs) are the regions where BC cel

154 primary breast tumours to that in metastatic axillary lymph nodes and to determine the correlation be

155 mance of breast MRI in diagnosing metastatic axillary lymph nodes based on the pathological result.

156 Two of the 11 axillary lymph nodes contained metastatic carcinoma.

157 Two hundred and twenty-seven axillary lymph nodes from preoperative breast MRIs were

158 lymph nodes metastasis and the diagnosis of axillary lymph nodes in patients with breast cancer is i

159 Axillary lymph nodes marked with a clip can be localized

160 It is difficult to accurately assess axillary lymph nodes metastasis and the diagnosis of axi

161 ne mastectomy and had at least four positive axillary lymph nodes or primary tumour stage T3-4 diseas

162 ll carcinoma and breast cancer metastases to axillary lymph nodes resulted in areas under the curve a

163 While the mean ADC value of malignant axillary lymph nodes was 0.749 10(-3) mm(2)/s (0.48-1.34

164 imination power between benign and malignant axillary lymph nodes was as follows: sensitivity - 60%;

165 Prior to NST, proven tumor-positive axillary lymph nodes were marked with a I seed.

166 immune response in primary tumors and in the axillary lymph nodes with metastasis (ALN(+)) in breast

167 immune cells in the primary tumor and in the axillary lymph nodes without metastasis (ALN(-)) differe

168 uding internal mammary, supraclavicular, and axillary lymph nodes) (nodal-irradiation group) or whole

169 tution, prior taxane-based therapy, involved axillary lymph nodes, and centrally determined phenotype

170 were obtained for the primary breast tumor, axillary lymph nodes, and extraaxillary lymph nodes on e

171 were obtained for the primary breast tumor, axillary lymph nodes, and extraaxillary lymph nodes.

172 ith combined ART, uptake of [18F]-FDG in the axillary lymph nodes, as measured by TBR, decreased from

173 and high NPV (96.4%) in detecting metastatic axillary lymph nodes, but its specificity was only fair

174 ion took into account the number of involved axillary lymph nodes, clinical tumour stage, oestrogen-r

175 d cervical lymph nodes but fewer than 20% of axillary lymph nodes, livers, brown fat samples, kidneys

176 ly 3 cm on exam, and multiple palpable right axillary lymph nodes.

177 multiple conglomerated 1-2 cm level I and II axillary lymph nodes.

178 ologic complete response (pCR) in breast and axillary lymph nodes.

179 There was no evidence of enlarged axillary lymph nodes.

180 ed between primary breast tumours and paired axillary lymph nodes.

181 sentinel-lymph-node involvement, completion axillary-lymph-node dissection can be omitted or replace

182 The previously undisputed gold standard of axillary-lymph-node dissection for staging has now been

183 s determined in patients undergoing complete axillary lymphadenectomy (ALND).

184 cal examination revealed no palpable mass or axillary lymphadenopathy.

185 ode biopsies has increased the complexity of axillary management, and any policy of de-escalation and

186 l response with resolution of the breast and axillary masses on exam.

187 hich differentiate in the final iteration of axillary meristem branching.

188 x) gene, which is expressed primarily in the axillary meristem dome and primordia and in developing s

189 ng directly controls boundary domains during axillary meristem formation and define a fundamental mec

190 ow that STM mobility is required to suppress axillary meristem formation during embryogenesis, to mai

191 HLH) transcriptional regulator necessary for axillary meristem formation that shows a striking bounda

192 A TARANU transcription factors have roles in axillary meristem initiation.

193 tant, indicating that GA biosynthesis in the axillary meristem is essential for inducing stolon diffe

194 anchors STM to activate STM as well as other axillary meristem regulatory genes.

195 iffuse vascular bundles in the nodes and the axillary meristem.

196 Axillary meristems (AMs) give rise to lateral shoots and

197 rsity of plant architecture is determined by axillary meristems (AMs).

198 the number, the position and the fate of the Axillary Meristems (AMs).

199 n a TCP transcription factor is expressed in axillary meristems and binds to the promoter of WUSCHEL,

200 flower1, GA2oxidase, and TPPI could protect axillary meristems in phyB-1 from precocious floral indu

201 When FveGA20ox4 is mutated, axillary meristems remain dormant or produce secondary s

202 To ensure the proper formation of new axillary meristems, the specification of boundary region

203 ranching is achieved by stem-cell-containing axillary meristems, which are initiated from a leaf axil

204 a plants display a squa phenotype developing axillary meristems, which can eventually turn into inflo

205 y the organization and developmental fate of axillary meristems.

206 tages II to III with cytologically confirmed axillary metastases between 1989 and 2007 who received P

207 tional responders to NCT with a low risk for axillary metastases when breast pCR is documented who ma

208 28 of 29 [96%] for readers 3 and 4, P = .50; axillary metastatic disease: seven of eight [88%] for re

209 he roles of preoperative imaging in defining axillary nodal burden, deselection of patients for senti

210 Patients with axillary nodal involvement after neoadjuvant systemic th

211 r, Houston, Texas, included 12 patients with axillary nodal metastases confirmed by results of fine-n

212 Of 21 patients with pathologically proven axillary nodal metastases, (18)F-fluciclovine-avid axill

213 breast cancer were reviewed to evaluate the axillary nodal staging by using the morphological charac

214 Specificity of breast MRI for axillary nodal staging was 57.8% (44.8-70.1%) and the po

215 Sensitivity of breast MRI for axillary nodal staging was 98.5% (95% CI: 92-100%), and

216 In view of the declining influence of axillary nodal status on adjuvant therapy decision-makin

217 Fine needle aspiration of a right axillary node confirmed metastatic carcinoma.

218 e underwent partial mastectomy, with partial axillary node dissection and sentinel node mapping.

219 breast cancer, she underwent mastectomy and axillary node dissection for a left-sided breast cancer

220 breast cancer, she underwent mastectomy and axillary node dissection for a left-sided breast cancer,

221 and in the presence of a technical failure, axillary node dissection should be performed.

222 She underwent quadrantectomy and axillary node dissection.

223 surgeon recommended a right mastectomy with axillary node dissection.

224 udy, including 6 who underwent mastectomy or axillary node dissection.

225 aditional RS risk groups among patients with axillary node-negative (N0) and limited node-positive (N

226 For patients with hormone receptor-positive, axillary node-negative breast cancer whose tumors have O

227 epidermal growth factor receptor 2-negative, axillary node-negative breast cancer, in whom an assay o

228 rs at the time of study entry; 157 (11%) had axillary node-negative disease; 1142 (76%) had ER-positi

229 Patients with axillary node-negative or nodal micrometastases, estroge

230 3 cm or less (pT1-2), none to three positive axillary nodes (pN0-1), and minimum microscopic margins

231 y its use without needing to know additional axillary nodes are involved.

232 dence of distant metastases, but up to three axillary nodes could be positive) breast cancer (tumour

233 RNA-sequencing of axillary nodes from StMSI1-OE and StBMI1-1-AS lines reve

234 east cancers in 17 patients, and 19 positive axillary nodes in eight patients.

235 tients randomized to ALND had a median of 17 axillary nodes removed compared with a median of only 2

236 ry nodal metastases, (18)F-fluciclovine-avid axillary nodes were seen in 20.

237 ccompanied by aerial stolons and tubers from axillary nodes, similar to miR156-OE lines.

238 1-2 breast cancer with one to three positive axillary nodes.

239 astatic carcinoma was identified in 10 of 13 axillary nodes.

240 the primary tumor with associated pathologic axillary outcome.

241 The long-term effect of axillary pathologic complete response (pCR) on survival

242 Overall axillary pathologic complete response rate was 37%.

243 5% CI, 46%-53%) (P < .001) for patients with axillary pCR and residual axillary disease, respectively

244 (95% CI, 18%-68%) (P < .001) for those with axillary pCR and residual axillary disease, respectively

245 d high rates of axillary pCR, and those with axillary pCR had excellent 10-year OS.

246 We retrospectively analyzed the effect of axillary pCR on 10-year OS and RFS among all women who r

247 Axillary pCR was associated with improved 10-year OS and

248 For patients with axillary pCR, 10-year OS rates were 90% (95% CI, 84%-94%

249 for HER2-positive disease had high rates of axillary pCR, and those with axillary pCR had excellent

250 A total of 454 (28.4%) achieved axillary pCR.

251 ositive disease, 67.1% (100 of 149) achieved axillary pCR; 10-year OS rates were 92% (95% CI, 84%-96%

252 ode dissection can be omitted or replaced by axillary radiotherapy, reducing morbidity.

253 Axillary recurrence rate was 0.2% and 1.4% for SLNB and

254 tics, crossover rates, blue node metastases, axillary recurrence, and lymphedema as measured by volum

255 ates of metastases in noncrossover nodes and axillary recurrences are low.

256 During a mean follow-up of 19 mo, no axillary recurrences were observed.

257 val after SLN alone was 93% with no isolated axillary recurrences.

258 Axillary reverse mapping (ARM) facilitates identificatio

259 hoxazole, a drug metabolite, was detected in axillary samples.

260 ll as the expected medial, pleural series of axillary sclerites.

261 Thorns arise from axillary shoot apical meristems that proliferate for a t

262 -mediated stable transformation system using axillary shoots as the initial explant.

263 zed to undergo ALND after SLND or no further axillary specific treatment.

264 The clinical interest of axillary staging after neoadjuvant chemotherapy is incre

265 Optimal axillary staging after neoadjuvant systemic therapy (NST

266 e lymph node appears to be most accurate for axillary staging after NST.

267 Axillary staging by a combination procedure consisting o

268 troduced as a new standard for less invasive axillary staging in breast cancer (BC) patients undergoi

269 and provide a minimally invasive method for axillary staging of breast cancer.

270 to assess the accuracy of different surgical axillary staging procedures compared with ALND.

271 for studies comparing less invasive surgical axillary staging procedures to ALND to identify axillary

272 opsy (SLNB) has become the gold standard for axillary staging.

273 nt if the SNs are negative), irrespective of axillary status beforehand, without affecting OS or DFS.

274 Women were stratified by post-PST axillary status, and survival outcomes were estimated an

275 Both A (radial/brachial) and B (axillary/subclavian/innominate) variants exhibited conco

276 st cancer patients undergoing more extensive axillary surgery and nodal radiotherapy did not experien

277 fter neoadjuvant therapy, patients underwent axillary surgery and the pathology of the clipped node w

278 ded into the following 4 groups according to axillary surgery approach: sentinel lymph node biopsy (S

279 ith future clinical trials to investigate if axillary surgery can be safely omitted in these selected

280 he risk for missing nodal metastases without axillary surgery in this cohort is extremely low.

281 alternative to SLNB in these patients, where axillary surgery is no longer considered therapeutic, an

282 of surgical morbidity by restricting further axillary surgery or considering radiotherapy in patients

283 Thereby, the need for axillary surgery should be reconsidered as well.

284 phedema, the main risk factor is the type of axillary surgery used.

285 Axillary surgery was performed with or without SLNB, TLN

286 tomy, who previously underwent breast and/or axillary surgery, or who received preoperative/neoadjuva

287 motherapy and is easily performed with other axillary surgery, such as SLN dissection.

288 S is recommended after chemotherapy to guide axillary surgery.

289 Axillary sweat was obtained from 30 healthy male donors

290 Dedicated high-spatial-resolution axillary T2-weighted MR imaging showed good specificity

291 esented with tympanic (>/=38.0 degrees C) or axillary temperature (>/=37.5 degrees C).

292 m participants >/=2 years of age with fever (axillary temperature of >/=37.5 degrees C) or with a his

293 Axillary temperature was 0.5 +/- 0.2 degrees C below cor

294 ae and sheaths, and between the mainstem and axillary tillers) to model the dynamics of canopy develo

295 pN0, patients generally received no further axillary treatment (SNB only); if the SNs were pN1, comp

296 ked lymph node may be used to tailor further axillary treatment after NST.

297 otherapy can be offered SNB (with no further axillary treatment if the SNs are negative), irrespectiv

298 Assess the performance characteristics of axillary ultrasound (AUS) for accurate exclusion of clin

299 d across other end product variables such as axillary vein damage (P = 0.864) and long thoracic nerve

300 Vascular access was via the left axillary vein.